Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936349 · ClinicalTrials.gov registry record
Graded TTCE for Post-Embolization PAVM Monitoring
A clinical trial of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by University of Pennsylvania.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT02936349 is a study of Hereditary Hemorrhagic Telangiectasia (HHT) that has completed, run by University of Pennsylvania. The registered enrollment target is 32 participants, below the 76-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02936349, a study of Hereditary Hemorrhagic Telangiectasia (HHT), has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to embolization. This study's purpose is to evaluate whether TTCE shunt grade can also accurately predict PAVM size and amenability to treatment in patients who are post-embolization.
Conditions Studied
Interventions
- OTHER Transthoracic Contrast Echocardiogram
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02936349
The ClinicalTrials.gov registry entry for NCT02936349 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (58% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 1 intervention - of which Transthoracic Contrast Echocardiogram is the first listed.
NCT02936349 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02936349 about?
NCT02936349 is a clinical study titled "Graded TTCE for Post-Embolization PAVM Monitoring". Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to emb...
What is the current status of trial NCT02936349?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2016-10. Estimated completion is 2019-11.
What conditions does trial NCT02936349 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT02936349?
The interventions under investigation include: Transthoracic Contrast Echocardiogram (OTHER).
Who is sponsoring clinical trial NCT02936349?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02936349 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
RECRUITING · Phase 1
-
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
ACTIVE NOT RECRUITING
-
Assess Safety and Efficacy of VAD044 in HHT Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.